Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
Massimo Offidani,1 Laura Corvatta,2 Sonia Morè,1 Attilio Olivieri1 1Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Ancona, Italy; 2U.O.C. Medicina, Ospedale Profili, Fabriano, ItalyCorrespondence: Massimo OffidaniClinica di Ematologia Azienda Ospedaliero-Univers...
Saved in:
Main Authors: | Offidani M (Author), Corvatta L (Author), Morè S (Author), Olivieri A (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2021-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
by: Jon Collins, et al.
Published: (2023) -
Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
by: Shah A, et al.
Published: (2021) -
Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
by: Chetan Rathi, et al.
Published: (2021) -
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
by: Joseph NS, et al.
Published: (2021) -
Novel Experimental Drugs for Treatment of Multiple Myeloma
by: Offidani M, et al.
Published: (2021)